FDA gives the green light to As­traZeneca's rare blood dis­or­der drug Voydeya, fol­low­ing ap­proval in Japan

As­traZeneca’s Voydeya, an add-on treat­ment for a rare dis­or­der in which red blood cells break up too ear­ly, scored ap­proval in the US, fol­low­ing in the foot­steps of a Japan ap­proval in Jan­u­ary.

The oral fac­tor D in­hibitor, called dan­i­co­pan and mar­ket­ed as Voydeya, is an add-on ther­a­py to As­traZeneca’s block­busters Soliris and Ul­tomiris for the treat­ment of ex­travas­cu­lar he­mol­y­sis (EVH) in adults with parox­ys­mal noc­tur­nal he­mo­glo­bin­uria (PNH).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.